These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1412 related articles for article (PubMed ID: 30482910)

  • 1. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kazankov K; Jørgensen SMD; Thomsen KL; Møller HJ; Vilstrup H; George J; Schuppan D; Grønbæk H
    Nat Rev Gastroenterol Hepatol; 2019 Mar; 16(3):145-159. PubMed ID: 30482910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Manne V; Handa P; Kowdley KV
    Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
    Kjær MB; George J; Kazankov K; Grønbæk H
    Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):51-64. PubMed ID: 32878486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural products that target macrophages in treating non-alcoholic steatohepatitis.
    Li CL; Zhou WJ; Ji G; Zhang L
    World J Gastroenterol; 2020 May; 26(18):2155-2165. PubMed ID: 32476782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments.
    Kitade H; Chen G; Ni Y; Ota T
    Nutrients; 2017 Apr; 9(4):. PubMed ID: 28420094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics.
    Nagashimada M; Honda M
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel insights into macrophage immunometabolism in nonalcoholic steatohepatitis.
    Yuan Y; Zhang Y; Lu X; Li J; Wang M; Zhang W; Zheng M; Sun Z; Xing Y; Li Y; Qu Y; Jiao Y; Han H; Xie C; Mao T
    Int Immunopharmacol; 2024 Apr; 131():111833. PubMed ID: 38503012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.
    de Faria Ghetti F; Oliveira DG; de Oliveira JM; de Castro Ferreira LEVV; Cesar DE; Moreira APB
    Eur J Nutr; 2018 Apr; 57(3):861-876. PubMed ID: 28875318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage metabolism in nonalcoholic fatty liver disease.
    Zhang W; Lang R
    Front Immunol; 2023; 14():1257596. PubMed ID: 37868954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary Lipids Differentially Shape Nonalcoholic Steatohepatitis Progression and the Transcriptome of Kupffer Cells and Infiltrating Macrophages.
    McGettigan B; McMahan R; Orlicky D; Burchill M; Danhorn T; Francis P; Cheng LL; Golden-Mason L; Jakubzick CV; Rosen HR
    Hepatology; 2019 Jul; 70(1):67-83. PubMed ID: 30516830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage p38α promotes nutritional steatohepatitis through M1 polarization.
    Zhang X; Fan L; Wu J; Xu H; Leung WY; Fu K; Wu J; Liu K; Man K; Yang X; Han J; Ren J; Yu J
    J Hepatol; 2019 Jul; 71(1):163-174. PubMed ID: 30914267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Macrophage heterogeneity role in NAFLD and NASH disease progression].
    Yang T; Wang X; Jiang LF; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jul; 31(7):770-775. PubMed ID: 37580264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
    Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y
    J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNF-Like Ligand 1 Aberrance Aggravates Nonalcoholic Steatohepatitis via M1 Macrophage Polarization.
    Luo Y; Guo J; Jia W; Wu M; Yin F; Niu G; Shih DQ; Targan SR; Zhang X
    Oxid Med Cell Longev; 2021; 2021():3877617. PubMed ID: 35003513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis.
    Li H; Zhou Y; Wang H; Zhang M; Qiu P; Zhang M; Zhang R; Zhao Q; Liu J
    Front Immunol; 2020; 11():1169. PubMed ID: 32670278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis.
    Wang X; Hausding M; Weng SY; Kim YO; Steven S; Klein T; Daiber A; Schuppan D
    Antioxid Redox Signal; 2018 Jan; 28(2):87-109. PubMed ID: 28635324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis.
    Chackelevicius CM; Gambaro SE; Tiribelli C; Rosso N
    World J Gastroenterol; 2016 Nov; 22(41):9096-9103. PubMed ID: 27895397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease.
    Nati M; Chung KJ; Chavakis T
    J Innate Immun; 2022; 14(1):31-41. PubMed ID: 34515137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Cha JY; Kim DH; Chun KH
    Lab Anim Res; 2018 Dec; 34(4):133-139. PubMed ID: 30671098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.